| Date Filed | Type | Description |
| 06/27/2016 |
3
| Seawell Haygood Paterson Sr (Private Investor) has filed a Form 3 on BG Medicine, Inc. |
| 06/23/2016 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/05/2016 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 05/04/2016 |
4
| Adourian Aram S. (SVP & Chief Scientific Officer) has filed a Form 4 on BG Medicine, Inc.|
Txns:
| Exercised 12,000 options to buy
@ $0.9, valued at
$10.8k
|
|
| 04/29/2016 |
10-K/A
| Annual Report for the period ended December 31, 2015 [amend] |
| 04/04/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 04/04/2016 |
4
| HALL STEPHEN P (EVP & CFO) has filed a Form 4 on BG Medicine, Inc. |
| 04/04/2016 |
4
| Adourian Aram S. (SVP & Chief Scientific Officer) has filed a Form 4 on BG Medicine, Inc. |
| 04/04/2016 |
4/A
| HALL STEPHEN P (EVP & CFO) has filed a Form 4 on BG Medicine, Inc. |
| 04/04/2016 |
4/A
| Adourian Aram S. (SVP & Chief Scientific Officer) has filed a Form 4 on BG Medicine, Inc. |
| 04/04/2016 |
10-K
| Annual Report for the period ended December 31, 2015 |
| 04/01/2016 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 03/31/2016 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 03/31/2016 |
8-K
| Quarterly results |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/29/2016 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 02/05/2016 |
4
| LUBER JEFFREY R (Director) has filed a Form 4 on BG Medicine, Inc. |
| 02/05/2016 |
3
| LUBER JEFFREY R (Director) has filed a Form 3 on BG Medicine, Inc. |
| 02/04/2016 |
8-K
| Form 8-K - Current report |
| 01/19/2016 |
SC 13G/A
| Empery Asset Management, LP reports a 5% stake in BG Medicine, Inc. |
| 12/23/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/04/2015 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 11/30/2015 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/23/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 11/20/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/17/2015 |
8-K
| Quarterly results|
Docs:
|
"BG Medicine Reports Third Quarter 2015 Financial Results Waltham, Mass., November 17, 2015 - BG Medicine, Inc. , the developer of the BGM Galectin-3 ® Test, today reported financial results for the three and nine months ended September 30, 2015. “Our operating results in the third quarter of 2015 reflect our ongoing efforts to extend our cash runway through the prudent and disciplined management of our resources, “ said Paul R. Sohmer, M.D., President and CEO of BG Medicine . “The commercialization of automated testing for galectin-3 in the U.S. was initiated in the third quarter. As a result, we continue to expect that product fees generated through the initial sales of automated tests for galectin-3 in the U.S. and payable to the Company by Abbott will be reported next quarter.” Third Qu..." |
|
| 11/16/2015 |
10-Q
| Quarterly Report for the period ended September 30, 2015 |
| 09/25/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|